DRUG NAME Escitalopr am Brand name: Lexapro Classificati on: antidepres sant Dose/rout e: 10mg PO

MECHANISM INDICATION CONTRAINDICATION OF ACTION Potentiates Treatment of Contraindicated with serotonergic major MAOI use; with allergy activity in the depressive to drug or CNS by disorder to citalopram or any inhibiting component of the reuptake of Maintenanc serotonin drug. e treatment resulting in for patients Use cautiously in the antidepressan with major elderly, and with renal t effect with depressive or hepatic impairment, little effect on norepinephrin disorder illnesses of e or metabolism Treatment of dopamine; an or hemodynamic resp generalized isomer of onse, pregnancy, anxiety citalopram lactation, suicidal disorder patients, patients with Unlabeled mania or seizure use: Panic disorders. disorder

ADVERSE EFFECTS

NURSING INTERVENTION

CNS: Somnolence, dizziness, insomnia, fatigue Dermatologic: Sweating GI: Nausea, dry mouth, constipation, diarrhea, indigestion, abdominal

Monitor patient for risk of suicidality, especially when starting or altering dosage; children and adolescents at increased risk. Administer once a day, in the morning or the evening; may be taken with food if desired.

pain, decreased appetite GU: Ejaculatory disorders, impotence, anorgasmia i n females, decreased libido Respiratory: Rhinitis, sinusitis, flu like symptoms

Encourage patient to continue use for 46 weeks, as directed, to ensure adequate levels to affect depression.

Limit amount of drug given in prescription to potentially suicidal patients. Advise any depressed patients to avoid the use of alcohol while being

treated with antidepressive drugs. Establish appropriate safety precautions if patient experiences adverse CNS effects. Institute appropriate therapy for patient suffering from depression. Encourage patient to void before taking the drug to help decrease anticholi nergic effects of urinary retention.

Olanzapin e

Brand name: Zyprexa Classificati on: Antipsych otic Dose/rout e: 2mg tab

blocks dopamine receptors in the brain, depresses the RAS; blocks serotonin receptor sites; anticholinergi c, antihistaminic (H1), and alphaadrenergic blocking

Treatment of schizophreni a Treatment of acute mixed or manic episodes associated with bipolar 1 disorder and maintenanc e of bipolar

Contraindicated with allergy to olanzapine, myelopr oliferative disorders, severe CNS depression, comatose states, lactation.

CNS: Somnolence, dizziness, nervousness, headache, akathisia, personality disorders, tardive dyskinesia, neur oleptic malignant syndrome CV: Orthostatic hypotension, peripheral edema, tachycardia GI: Constipation, abdominal pain Respiratory: Cough, pharyngitis Other: Fever, weight gain, joint pain, development of diabetes mellitus

Use cautiously in elderly or debilitated patients, or with CV or cerebrovascular disease, dehydration, seizure disorders,

Monitor for elevations of temperature and differentiate between infection and neuroleptic ma

activity may contribute to some of its therapeutic (and adverse) actions; produces fewer extrapyramid al effects than mostantipsyc hotics.

1 disorder as monotherap y, or combined with lithium or valproate Treatment of agitation associated with schizophreni a and bipolar 1 mania (injection)

Alzheimers disease, prostate enlargement, narrow-angle glaucoma, history of paralytic ileus or breast cancer, pregnancy; phenylketonuria (if using orally disintegrating tablets, contain phenylalanine).

lignant syndrome.

Monitor for orthostatic hypotension and provide appropriate safety measures as needed. Monitor patient regularly for signs and symptoms of diabetes mellitus.